DUBLIN–(BUSINESS WIRE)–The “Overview
of the Japanese CRO Market 2019” report has been added to ResearchAndMarkets.com’s
offering.
This report takes an overview of the CRO market in Japan. By reading
this report, readers will understand the overall picture of the Japanese
CRO market, including the market size trends, major CRO players, in
addition to the competitive differences between local and global CROs.
The Japanese CRO market has been expanding in recent years, and it
reached over 180 Yen billion in 2017.
When the market is broken down by functional services, monitoring
accounted for 58% of the total market and followed by data management
with 14%.
Phase III occupies 42.2%, followed by PMS; post-marketing surveillance
with 9.9%, and phase II with 9.2%.
There is still some room for pharma to outsource clinically related
works. The rate of outsourcing will also increase a little in the coming
years. Furthermore, the shortage of operational resources in pharma in
the last 5 years enhanced the outsourcing works from pharma to CROs.
Japan may face a situation in which it loses some clinical trials to
other regions, especially China in the near future. As trials shift to
global studies from local ones, this tendency will increase over time.
Clients have introduced a preferred/strategic partnership model with top
6 CROs mentioned earlier, especially IQVIA. IQVIA had to turn down many
of projects due to resource constraint in the last 5 years, and other
CROs could reap the benefits, taking over those projects from IQVIA. The
resource issue in CROs is now quickly resolving, as pharma is cutting
many jobs and people are flowing into CROs. Due to better capability in
global CROs, clients are shifting to selected global CROs, and this will
increase over time.
Key Topics Covered:
- Summary
- Definition of CRO Market
- Clinical Trial Trend
- Challenges when conducting clinical trails in Japan
- CRO market size
- CRO market breakdown by service
- CRO market breakdown by phase
- Key Industry Association
- Major CRO companies
-
Top 6 CROs
- CMIC
- EPS
- IQVIA
- Parexel
- A2 Healthcare
- M3 Group
-
Other players globally
- PPD-SNBL
- Syneos Health
- ICON
- Clinical Trial Trend
- Increasing Outsourcing in Pharma
- Shift of Multinational Clinical Trials
- Contrast of Japanese and foreign CROs
- Strategic partnership model
- Future outlook
For more information about this report visit https://www.researchandmarkets.com/r/toqczl
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Drug
Discovery